Octapharma - Blood Disorder Treatment products (inc Haemophilia A & B)
Norfolk and Norwich University Hospitals NHS Foundation Trust · awarded 1 January 2025 · delivered in East of England
£72k
Award value
£71,550
1
Supplier
Recorded as a small or medium-sized business
30 Apr 2027
Runs until
from 1 Jan 2025
Who
| Buyer | Norfolk and Norwich University Hospitals NHS Foundation Trust Norwich |
|---|---|
| Supplier |
Octapharma Limited |
| Category | goods |
| Classification | Pharmaceutical products CPV 33600000 |
| Notice published | 12 March 2025 |
What it is for
Call off contract/order from the NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A & B. Offer reference number: CM/PHS/22/5661 Specifically for products: Fibryga Octaplas
Read the original award notice on Contracts Finder →
Other contracts from this buyer
188 awards on file, worth £169.3m.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 18 Jun 2024 | Meditech Electronic Patient Record - NNUHEast of England | Norfolk and Norwich University Hospitals NHS… | MEDITECH UK | £80.7m |
| 17 Apr 2025 | Leica Biosystems - Cellular Pathology - MSCEast of England | Norfolk and Norwich University Hospitals NHS… | LEICA MICROSYSTEMS (UK) LIMITED | £9.0m |
| 6 Dec 2024 | EPR Design, Build, and Test Implementation PartnerEast of England | Norfolk and Norwich University Hospitals NHS… | THE BOSTON CONSULTING GROUP UK LLP | £5.8m |
| 27 Jan 2026 | Roche - Point of Care Testing (POCT) Managed Service ContractEast of England | Norfolk and Norwich University Hospitals NHS… | ROCHE DIAGNOSTICS LIMITED | £5.4m |
| 31 Jan 2025 | bioMerieux Ltd - Bacteriology managed serviceEast of England | Norfolk and Norwich University Hospitals NHS… | BIOMERIEUX UK LIMITED | £4.4m |
Everything Norfolk and Norwich University Hospitals NHS… has awarded →
Other contracts won by this supplier
3 awards on file, worth £1.7bn.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 19 Dec 2024 | NHS Framework Agreement for Human Albumin & Normal and Anti-D ImmunoglobulinScotland | NHS England | CSL Behring UK Ltd +5 | £905.2m |
| 31 May 2024 | NHS Framework - Blood Disorders including Haemophilia A and B - July 2024East Midlands | NHS England | Pfizer Ltd +8 | £765.0m |
| 1 Jan 2025 | Octapharma - Blood Disorder Treatment products (inc Haemophilia A & B)East of England | Norfolk and Norwich University Hospitals NHS… | Octapharma Limited | £72k |